Summary
This study is testing a new medicine called PF-08634404 in people with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body.
Researchers want to learn:
- How safe PF-08634404 is
- How well it works against cancer
- How the body processes the medicine
- How the medicine affects cancer-related markers in the body
Who can take part?
You may be able to join if you:
- Are aged 18 years or older
- Have locally advanced or metastatic urothelial cancer
What treatment will I receive?
Participants in this study will be placed in one of two groups:
- Cohort A:
- For people who have previously received treatment for their cancer
- Participants will receive PF-08634404 on its own
- Cohort B:
- For people who have not received treatment for their advanced cancer
- Participants will receive PF-08634404 together with another medicine called enfortumab vedotin
The study medicines are given through a drip into a vein (intravenous or IV infusion).
What does participation involve?
Before starting treatment, you will complete a screening period to check whether the study is suitable for you.
During the study, you will attend regular clinic visits for:
- Treatment
- Physical examinations and health checks
- Blood tests and other assessments
- Scans to monitor your cancer and see how it is responding to treatment
Treatment will continue for as long as it is helping control the cancer and side effects remain manageable.
In some situations, if scans show that the cancer has grown but your doctor believes you are still benefiting from treatment and side effects are manageable, you may be able to continue treatment with approval from both your doctor and the study sponsor.